Pathway for MASLD and MASH

CE / CME

Clinical Care Pathway: A Framework for Managing MASLD/MASH

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurses: 0.50 Nursing contact hour

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Released: January 31, 2024

Expiration: January 30, 2025

Arun B. Jesudian
Arun B. Jesudian, MD

Activity

Progress
1 2
Course Completed

Introduction

In this module, Arun B. Jesudian, MD, discusses a management paradigm for metabolic dysfunction–associated steatotic liver disease (MASLD), metabolic dysfunction–associated steatohepatitis (MASH), and advanced fibrosis. These terms were updated in summer 2023 and are used in replacement of nonalcoholic fatty liver disease (NAFLD, now MASLD) and nonalcoholic steatohepatitis (NASH, now MASH) per the goal of multinational liver associations and patient advocates of aligning nomenclature with the metabolic nature of these liver conditions.1 In this text module, Dr Jesudian provides key insights regarding the management of patients with MASLD/MASH based on the American Gastroenterological Association (AGA) Clinical Care Pathway and evidence-based treatment strategies.2-4  

The key points discussed in this module are illustrated with thumbnails from an accompanying downloadable PowerPoint slideset, which can be found here or by clicking on any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Several questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many patients with MASH do you provide care for in a typical week?

Reversal of fibrosis in MASLD/MASH has been shown with which of the following weight loss thresholds? 

A 57-year-old female patient with type 2 diabetes (T2D) (controlled on max dose of metformin) presents with elevated liver function tests and a positive ultrasound for liver echogenicity. She is diagnosed with MASH and F3 fibrosis. She has a BMI of 32 kg/m2. Which of the following would be the best treatment option for her?